Drugs · Entity Annotation Prototype (beta)

1articles mentioning drugs

1drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: IV Pembrolizumab ×

IV Pembrolizumab

This drug is selected. Its supporting articles are shown below.

IV Pembrolizumab1

Articles mentioning IV Pembrolizumab

1 articles · page 1 of 1

1343 A phase II trial of combination locoregional chemoimmunotherapy in recurrent platinum-sensitive ovarian cancer triggers a T lymphotactic response correlating with clinical outcomes

jitc · abstract · 2025-11-07 · 1 matching annotations

91.8%

IV Pembrolizumab cisplatin Rintatolimod Merck AIM Immunotech Epithelial ovarian cancer EOC

…up to six treatment cycles at 3-week intervals of IP cisplatin, IV Pembrolizumab and IP TLR3 ligand Rintatolimod. The primary outcome was object…

Browse drugs

IV Pembrolizumab

Articles mentioning IV Pembrolizumab

1343 A phase II trial of combination locoregional chemoimmunotherapy in recurrent platinum-sensitive ovarian cancer triggers a T lymphotactic response correlating with clinical outcomes